Chemoinformaics analysis of LEVOPIMARIC-ACID
| Molecular Weight | 484.677 | nRot | 1 |
| Heavy Atom Molecular Weight | 440.325 | nRig | 30 |
| Exact Molecular Weight | 484.319 | nRing | 6 |
| Solubility: LogS | -4.672 | nHRing | 1 |
| Solubility: LogP | 4.226 | No. of Aliphatic Rings | 6 |
| Acid Count | 1 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 5 |
| Atoms Count | 79 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 35 | No. of Aromatic Carbocycles | 0 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 44 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 30 | No. of Saturated Rings | 5 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 5 | No. of Arom Bond | 0 |
| nHA | 4 | APOL | 83.4489 |
| nHD | 2 | BPOL | 47.6131 |
| QED | 0.477 |
| Synth | 6.063 |
| Natural Product Likeliness | 2.684 |
| NR-PPAR-gamma | 0.994 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.123 |
| Pgp-sub | 0.002 |
| HIA | 0.028 |
| CACO-2 | -5.398 |
| MDCK | 0.0000258 |
| BBB | 0.325 |
| PPB | 0.906712 |
| VDSS | 0.702 |
| FU | 0.0676117 |
| CYP1A2-inh | 0.001 |
| CYP1A2-sub | 0.494 |
| CYP2c19-inh | 0.011 |
| CYP2c19-sub | 0.937 |
| CYP2c9-inh | 0.104 |
| CYP2c9-sub | 0.302 |
| CYP2d6-inh | 0.001 |
| CYP2d6-sub | 0.137 |
| CYP3a4-inh | 0.194 |
| CYP3a4-sub | 0.457 |
| CL | 9.885 |
| T12 | 0.045 |
| hERG | 0.001 |
| Ames | 0.071 |
| ROA | 0.781 |
| SkinSen | 0.054 |
| Carcinogencity | 0.024 |
| EI | 0.242 |
| Respiratory | 0.962 |
| NR-Aromatase | 0.847 |
| Antiviral | Yes |
| Prediction | 0.703161 |